Dupixent (dupilumab) is a widely prescribed medication approved for treating several inflammatory conditions such as atopic dermatitis, asthma, and eosinophilic esophagitis (EoE). While it has brought relief to many patients, serious adverse effects have emerged post-approval, including eye disorders, paradoxical worsening of eosinophilic conditions, and a potential link to lymphoma. These risks are prompting a growing number of lawsuits against drug makers Sanofi and Regeneron Pharmaceuticals.
Currently, federal courts are seeing an emerging wave of Dupixent-related claims focused on failure-to-warn allegations. Though no multidistrict litigation (MDL) has yet been established, the cases are gaining momentum and may soon be centralized for coordinated handling. This article explains the known risks, the science behind them, who may be eligible to file a claim, and what steps injured patients should consider.
If you or a loved one took Dupixent and suffered serious side effects, understanding your rights is critical. The situation is evolving, but early action can preserve your legal options.
If you experienced severe eye problems, paradoxical eosinophilia, or lymphoma after using Dupixent, call Phillips Law Group for a free case review. We represent clients nationwide and handle mass tort claims involving dangerous drugs.
Call now: (602) 222-2222
Dupixent is a biologic medication developed by Sanofi and Regeneron Pharmaceuticals. It is FDA-approved for treating several type 2 inflammatory diseases, including moderate-to-severe atopic dermatitis (eczema), asthma, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis (EoE). Dupixent works by blocking interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling pathways, which play a key role in inflammation.
Since its approval, Dupixent has become one of the highest-grossing drugs globally, praised for its efficacy in reducing inflammation and improving symptoms. However, like many powerful immune-modulating drugs, it carries a risk of adverse effects that may be serious or unexpected.
Emerging evidence links Dupixent to several concerning side effects, particularly involving the eyes and immune system. Understanding the science helps explain why these issues occur and supports legal claims related to inadequate warnings.
“Post-market case series and FDA label updates acknowledge Dupixent-associated ocular surface disease and paradoxical eosinophilia, providing a scientific basis for failure-to-warn claims.”
These findings are supported by multiple peer-reviewed case series and FDA adverse event reports. The FDA’s drug database lists Dupixent’s approved uses and includes safety information that has been updated to reflect these risks.
Note: These criteria indicate cases with stronger claims but do not constitute legal advice. Each claim requires individual evaluation. Contact a qualified attorney to discuss your situation.
As of mid-2026, Dupixent lawsuits remain in the early stages. Plaintiffs have begun filing cases in various federal courts nationwide, primarily alleging failure to warn about serious risks such as ocular injuries, paradoxical eosinophilia, and lymphoma. The growing number of similar claims has led to calls for multidistrict litigation (MDL) consolidation to streamline pretrial proceedings.
Several courts are evaluating motions to centralize these cases under one judge, which would facilitate discovery and coordinated management. No MDL has been formally established yet, and trial dates or bellwether selections remain pending. The judge assigned to oversee any future MDL is still to be determined.
Defendants Sanofi and Regeneron have been served with complaints and are preparing responses. Settlement discussions have not yet begun, but plaintiffs’ attorneys are actively investigating FDA adverse event reports and scientific literature to build strong cases.
At Phillips Law Group, we understand the physical and emotional toll that serious drug injuries impose. Our nationwide personal injury attorneys have extensive experience handling mass tort claims against major pharmaceutical companies. We carefully evaluate emerging cases and represent clients fairly and aggressively.
We offer free consultations and work on a contingency fee basis, which means you pay nothing unless we recover compensation for you. Our team stays current on the latest legal and scientific developments in Dupixent litigation to protect your interests and fight for justice.
We represent clients nationwide in Dupixent lawsuits involving eye injuries, eosinophilia, and lymphoma. Protect your rights with trusted legal guidance.
Phillips Law Group provides this information as a service to the public. This content is not legal advice and does not create an attorney-client relationship. Consult a qualified attorney for advice about your individual situation.
Dupixent (dupilumab) has been hailed as a breakthrough medication for conditions like eczema, asthma, and chronic rhinosinusitis/sinusitis. However, recent evidence suggests the manufacturers may have failed to adequately warn patients and doctors about the potential risk of developing cancer, specifically cutaneous T-cell lymphoma (CTCL), after taking this medication. If you or a loved one developed cutaneous T-cell lymphoma after treatment with this drug, you may need the assistance of a Dupixent lawyer, and Phillips Law Group may be able to help.
A report published in the Journal of the American Academy of Dermatology (JAAD) in June 2025 found that “Cases of dupilumab treatment followed by cutaneous T-cell lymphoma (CTCL) diagnosis have been reported since dupilumab was approved for moderate-to-severe atopic dermatitis (AD) in 2017,” but that, “it may reflect dupilumab unmasking an underlying CTCL, dupilumab promoting lymphoid-reaction/CTCL under IL-13/IL-4 blockade, or CTCL developing in patients with advanced long-standing AD, regardless of treatment.”
However, another report published in the Journal of the American Academy of Dermatology in 2024 looked into the risk of CTCL after dupilumab use in patients with atopic dermatitis and found “an increased risk of CTCL was found in the cohort of AD patients who used dupilumab.” And there are other reports suggesting a link as well.
Ultimately, there is evidence that there could be a higher risk of developing CTCL after a patient takes Dupixent, and if you or a loved one were prescribed Dupixent and subsequently received a cancer diagnosis without this being a risk you were fully informed of, you deserve answers, justice, and compensation. Our team is here to assist you and discuss your legal options.
Our firm is investigating claims from individuals across the nation who believe their T-cell lymphoma was caused by this potentially dangerous drug. Phillips Law Group is adept at building robust litigation strategies to hold powerful pharmaceutical corporations accountable for their alleged failure to warn the public of severe side effects of drugs, and we want to get to the bottom of whether or not the manufacturers behind this medicine knew of the potential risks and didn’t warn patients appropriately.
We know the devastating impact of any cancer diagnosis, and if you or someone you love potentially received such a diagnosis because of taking a drug you believed would improve your health, not hurt it, you deserve justice. We have the resources and experience to aggressively pursue the compensation you may need for medical bills, pain and suffering, lost quality of life, and more.
Phillips Law Group has served our clients for more than 30 years, and we have secured more than $2 billion in settlements in that time. We believe we may be the right choice to partner with on a Dupixent lawsuit, and if we can’t assist you, we may be able to refer you to a firm that can.
Contact our dedicated personal injury lawsuit attorneys immediately for a free, confidential, and no-obligation case evaluation. You owe us nothing unless we take on your case and win it.
Let us fight for your rights while you focus on your health. Call 602-222-2222 or fill out the form on this page to get in touch now.
Available 24/7 
